De novo drug design aims to generate molecules from scratch that possess specific chemical and pharmacological properties. We present a computational approach utilizing interactome-based deep learning for ligand- and structure-based generation of drug-like molecules. This method capitalizes on the unique strengths of both graph neural networks and chemical language models, offering an alternative to the need for application-specific reinforcement, transfer, or few-shot learning. It allows for the construction of compound libraries tailored to possess specific bioactivity, synthesizability, and structural novelty. In order to proactively evaluate the deep interactome learning framework for structure-based drug design, potential new ligands t...
This work introduces a method to tune a sequence-based generative model for molecular de novo design...
© 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group. Introduction: Deep discrimin...
It is more pressing than ever to reduce the time and costs for the development of lead compounds in ...
Over several decades, a variety of computational methods for drug discovery have been proposed and a...
Recent years have seen tremendous success in the design of novel drug molecules through deep generat...
Drug discovery based on artificial intelligence has been in the spotlight recently as it significant...
Bridging systems biology and drug design, we propose a deep learning framework for de novo discovery...
Generative machine learning models sample drug-like molecules from chemical space without the need f...
Designing novel drugs is a complex process which requires finding molecules in a vast chemical space...
De novo drug design is a computational approach that generates novel molecular structures from atomi...
Automating the molecular design-make-test-analyze cycle accelerates hit and lead finding for drug di...
Generative chemical language models (CLMs) can be used for de novo molecular structure generation by...
Abstract In recent years, the field of computational drug design has made significant strides in the...
Drug discovery benefits from computational models aiding the identification of new chemical matter w...
In the scope of drug discovery, the molecular design aims to identify novel compounds from the chemi...
This work introduces a method to tune a sequence-based generative model for molecular de novo design...
© 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group. Introduction: Deep discrimin...
It is more pressing than ever to reduce the time and costs for the development of lead compounds in ...
Over several decades, a variety of computational methods for drug discovery have been proposed and a...
Recent years have seen tremendous success in the design of novel drug molecules through deep generat...
Drug discovery based on artificial intelligence has been in the spotlight recently as it significant...
Bridging systems biology and drug design, we propose a deep learning framework for de novo discovery...
Generative machine learning models sample drug-like molecules from chemical space without the need f...
Designing novel drugs is a complex process which requires finding molecules in a vast chemical space...
De novo drug design is a computational approach that generates novel molecular structures from atomi...
Automating the molecular design-make-test-analyze cycle accelerates hit and lead finding for drug di...
Generative chemical language models (CLMs) can be used for de novo molecular structure generation by...
Abstract In recent years, the field of computational drug design has made significant strides in the...
Drug discovery benefits from computational models aiding the identification of new chemical matter w...
In the scope of drug discovery, the molecular design aims to identify novel compounds from the chemi...
This work introduces a method to tune a sequence-based generative model for molecular de novo design...
© 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group. Introduction: Deep discrimin...
It is more pressing than ever to reduce the time and costs for the development of lead compounds in ...